C3L-02513
— · cohortA1
Clinical attributes
From the source cohort, normalized into canonical keys plus the project's native columns.
- cancer_type
- —
- cancer_type_detailed
- —
- subtype
- cohortA1
- subtype
- cohortA1
- age_years
- 73.95482546
GSVA pathway preview (50 Hallmark scores)
Top 10 most elevated and top 10 most suppressed Hallmark pathways for this sample.
Top 10 elevated
- PANCREAS_BETA_CELLS+0.400
- PEROXISOME+0.250
- BILE_ACID_METABOLISM+0.220
- KRAS_SIGNALING_DN+0.210
- KRAS_SIGNALING_UP+0.160
- ALLOGRAFT_REJECTION+0.150
- CHOLESTEROL_HOMEOSTASIS+0.100
- P53_PATHWAY+0.080
- ESTROGEN_RESPONSE_EARLY+0.070
- FATTY_ACID_METABOLISM+0.070
Top 10 suppressed
- E2F_TARGETS-0.580
- G2M_CHECKPOINT-0.520
- EPITHELIAL_MESENCHYMAL_TRANSITION-0.480
- MITOTIC_SPINDLE-0.440
- MTORC1_SIGNALING-0.410
- PI3K_AKT_MTOR_SIGNALING-0.310
- UNFOLDED_PROTEIN_RESPONSE-0.300
- MYC_TARGETS_V1-0.280
- ANGIOGENESIS-0.270
- DNA_REPAIR-0.270
Patient twins — nearest pathway neighbors
10 samples closest to this one in 50-dim pathway space, drawn from the Pathway Atlas. Cosine similarity = 1 means identical pathway state.
10 twins match this tumor's tissue · 0 come from a different tissue of origin
| # | Sample | Cancer type | Subtype | cos similarity |
|---|---|---|---|---|
| 1 | C3L-02350 | — | cohortA1 | 0.841 |
| 2 | a6136b7b.48bb.4ab0.809d.d89b1cae2837 | — | cohortA1 | 0.837 |
| 3 | C3L-02967 | — | cohortA2 | 0.824 |
| 4 | C3L-00368 | — | cohortA1 | 0.821 |
| 5 | C3N-03212 | — | cohortA1 | 0.814 |
| 6 | TCGA-44-7659-01A-11R-2066-07 | — | cohortA1 | 0.812 |
| 7 | TCGA-62-A46S-01A-11R-A24H-07 | — | cohortA3 | 0.807 |
| 8 | TCGA-91-A4BD-01A-11R-A24H-07 | — | cohortA1 | 0.792 |
| 9 | C3L-03679 | — | cohortA1 | 0.787 |
| 10 | C3L-02958 | — | cohortA1 | 0.786 |
Per-pathway drug coverage
For each elevated pathway in this tumor, the best-reversing drug across the catalog. Uncovered pathways = unmet need at pathway level for this one patient.
0 of 13 elevated pathways have at least one drug that meaningfully reverses them.
| Pathway (elevated) | tumor score | Best drug | reversal magnitude |
|---|---|---|---|
| PANCREAS_BETA_CELLS | 0.400 | Cobimetinib | — uncovered |
| PEROXISOME | 0.250 | Idelalisib | — uncovered |
| BILE_ACID_METABOLISM | 0.220 | Inavolisib | — uncovered |
| KRAS_SIGNALING_DN | 0.210 | Remibrutinib | — uncovered |
| KRAS_SIGNALING_UP | 0.160 | Inavolisib | — uncovered |
| ALLOGRAFT_REJECTION | 0.150 | Idelalisib | — uncovered |
| CHOLESTEROL_HOMEOSTASIS | 0.100 | Remibrutinib | — uncovered |
| P53_PATHWAY | 0.080 | Idelalisib | — uncovered |
| ESTROGEN_RESPONSE_EARLY | 0.070 | Inavolisib | — uncovered |
| FATTY_ACID_METABOLISM | 0.070 | Inavolisib | — uncovered |
| HEME_METABOLISM | 0.050 | Temsirolimus | — uncovered |
| NOTCH_SIGNALING | 0.050 | Inavolisib | — uncovered |
| PROTEIN_SECRETION | 0.020 | Remibrutinib | — uncovered |